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T cell activity is controlled by a combination of anti-
gen-dependent signaling through the T cell receptor
and a set of auxiliary signals delivered through anti-
gen-independent interactions, including the recogni-
tion of the B7 family of ligands. B7-H3 is a recently
identified B7 family member that is strongly overex-
pressed in a range of cancers and correlates with
poor prognosis. We report the crystal structure of
murine B7-H3 at a 3 A˚ resolution, which provides
a model for the organization of the IgV and IgC
domains within the ectodomain. We demonstrate
that B7-H3 inhibits T cell proliferation and show
that the FG loop of the IgV domain plays a critical
role in this function. B7-H3 crystallized as an unusual
dimer arising from the exchange of the G strands in
the IgV domains of partner molecules. This arrange-
ment, in combination with previous reports, high-
lights the dynamic nature and plasticity of the immu-
noglobulin fold.
INTRODUCTION
T cell activity is controlled by the integration of signals arising
from multiple molecular interactions on the cell surface. Accord-
ing to the canonical two-signal model, engagement between the
T cell receptor (TCR) and the antigenic peptide:major histocom-
patibility complex (pMHC) displayed on the surface of the
antigen-presenting cell (APC) (i.e., ‘‘signal 1’’) is essential but
not sufficient for activation of naive T cells in vivo. This antigen-
dependent signal requires additional antigen-independent sig-
nals, which can either lead to activation of T cells (e.g., through
formation of CD28:B7 complexes) or to downregulation of their
activity (e.g., through the formation of CTLA-4:B7 complexes).
The identification of the crucial costimulatory signal through
the CD28 receptor was prompted by the observation that in
the absence of B7-1 or B7-2 on the APC, engagement of the
TCR on naive T cells causes them to become nonresponsive
(i.e., anergic) (Sharpe and Freeman, 2002). Once activated,Structure 21T cells express the inhibitory CTLA-4 receptor, which also binds
(and, thus, competes with CD28 for) the B7-1 and B7-2 ligands,
providing a control mechanism for T cell proliferation (Sharpe
and Freeman, 2002). Additional sequence-related molecules
have since been identified and characterized as leading to stim-
ulation (e.g., ICOSL) or inhibition (e.g., PD-L1, PD-L2) of T cell
activity via engagement of their corresponding receptors (ICOS
and PD-1, respectively), thereby defining the B7 family of pro-
teins (Sharpe and Freeman, 2002). B7 family members belong
to the immunoglobulin (Ig) superfamily and, while sharing low
sequence identity, have a common domain structure and
interact with receptors belonging to the CD28 protein family
(Sharpe and Freeman, 2002; Hansen et al., 2009). In vivo, tissue
localization and timing of expression of these molecules provide
mechanisms for the fine-tuning of T cell activity in response to a
wide range of immune challenges.
B7-H3 is a recently recognized member of the B7 family. Like
other members, murine B7-H3 is a type 1 transmembrane pro-
tein possessing an ectodomain composed of a single IgV-IgC
domain pair with an overall sequence identity of %30%, when
compared to the other B7 family members. In the mouse, B7-
H3 transcripts are found in a variety of tissues, including brain,
lung, colon, kidney, and spleen (Sun et al., 2002, 2003; Ling
et al., 2003). Although initially identified as an activator of T cell
function (Chapoval et al., 2001), subsequent reports have shown
that B7-H3 can lead to downregulation of T cell activity (Suh
et al., 2003; Prasad et al., 2004).
B7-H3 protein is normally found at low levels in many healthy
tissues as well as on activated cells of the immune system and
has been reported to be strongly overexpressed in a wide variety
of human malignancies (Zang et al., 2007; Yamato et al., 2009;
Barach et al., 2010; Crispen et al., 2008; Roth et al., 2007;
Loos et al., 2010)—a scenario associated with poor clinical out-
comes. In particular, 93% of prostate cancers overexpress B7-
H3, and patients with higher levels of B7-H3 on tumor cells are
significantly more likely to exhibit disseminated disease at the
time of surgery, increased recurrence, and higher mortality
(Zang et al., 2007). In addition to cancer cells, B7-H3 is also ex-
pressed in the endothelium of cancer-associated vasculature in
44% of patients with ovarian cancer, which is associated with a
significantly shorter survival time and a higher incidence of recur-











































Figure 1. Expression and Purification of
mB7H3
(A) Domain organization of murine B7 family
members. Diagrams of murine B7-1 and B7-H3
are shown as the representative members of
the B7 family. Molecules are expressed as
type 1 transmembrane proteins, consisting of an
N-terminal IgV and a C-terminal IgC domains,
followed by a single transmembrane sequence
and a short cytoplasmic tail.
(B) Purified mB7H3 monomer and dimer species
are glycosylated and do not contain interchain
disulfide bonds. SDS-PAGE of purified monomer
(M) and dimer (D) forms of mB7H3 were separated
in the presence or absence of dithiothreitol and
before and after treatment with PNGase F, as
indicated above the lanes.
(C) Native mB7H3 expressed by Drosophila S2
cells behaves as a monomer in SEC. Purified
protein elutes as a monodisperse peak of40 kDa
on a calibrated Superdex 200 size-exclusion col-
umn (dark trace). Molecular weight standards are
shown (light trace). mAU, milliabsorbance unit.
Structure
B7-H3 Structure and T Cell Inhibitor Functionof B7-H3 to inhibit the activity and proliferation of T cells, suggest
that tumor cells use the signal delivered by B7-H3 to evade
antitumor immunity. The potential role in immune evasion makes
B7-H3 a compelling target for anticancer therapy.
We report the crystal structure of the extracellular domain
of murine B7-H3, which reveals an unusual organization
involving a strand swap between the dimer-forming IgV do-
mains. Based on this structure, a model of B7-H3 with canonical
interactions between the IgV and IgC domains was constructed
and used as the basis for mutagenesis studies that revealed a
critical role for the FG loop of the IgV domain in the ability of
mB7H3 to inhibit naive T cell proliferation in vitro. Our findings
provide insights for the structure-guided design of the next-gen-
eration cancer immunotherapeutics.
RESULTS
mB7H3 Is Produced by Drosophila S2 Cells
as a Glycosylated Monomer
B7 family members share low sequence identity but possess a
common domain structure (Figure 1A) and have a similar mode708 Structure 21, 707–717, May 7, 2013 ª2013 Elsevier Ltd All rights reservedof interaction with receptors belonging
to the CD28 protein family. The ectodo-
main of murine B7-H3 is composed of a
single IgV-IgC domain pair (amino acids
34–247) and was produced as a secreted
His6-tagged protein (mB7H3) using
Schneider 2 (S2) Drosophila cells.
Although the predicted molecular weight
of mB7H3 was 24 kDa, purified protein
behaved as an 40 kDa species (Fig-
ure 1B) in SDS-PAGE, indicating the pres-
ence of glycan modifications at some of
the four predicted N-linked glycosylation
sites (N91, N104, N189, and N215). The
presence of glycans was verified bydigestion with peptide N-glycosidase F (PNGase F), which
resulted in the reduction of the molecular weight of the mB7H3
to 30 kDa (Figure 1B). Native protein eluted as an 40 kDa
species in a size-exclusion chromatography (SEC) column (Fig-
ure 1C). Taken together, these data indicate that mB7H3 is
expressed as a glycosylated monomer.
Crystal Structure of mB7H3
To define the oligomeric organization of mB7H3 and predict its
receptor-binding surfaces, we determined its crystal
structure (Table 1). The mB7H3 crystals exhibited diffraction
consistent with the space group P6122 (a = 100.9 A˚, b =
100.9 A˚, c = 188.2 A˚; one molecule per asymmetric unit), which
extended to 2.97 A˚. The final refined model accounts for
residues 35–151 and 157–239 of mB7H3 with residues
152–156 omitted from the model due to poorly defined electron
density, whereas residues 240–247, although present in
the expression construct, were not observed in the electron
density.
Pairs of mB7H3 molecules related by crystallographic 2-fold
axes form extensive contacts, arising from the mutual exchange
Table 1. Crystallographic Statistics
Data Collection












I/s (I)a 18.1 (3.9)
Completeness (%)a 99.7 (100.0)
Redundancya 13.1 (13.7)
Refinement









Rmsd from Ideal Geometry
Bond lengths (A˚) 0.012
Bond angles () 1.7
Rmerge = S jI  <I>j/SI, where I is the integrated intensity of a given
reflection.
Rwork = S jjFobsj  jFcalcjj/S jFobsj.
Rfree was calculated using 5% of data omitted from refinement.
aThe highest-resolution shell is shown in parentheses.
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B7-H3 Structure and T Cell Inhibitor Functionof the IgV domains between the neighboring molecules (Fig-
ure 2A). The segment connecting F and G strands (the FG
loop) of the IgV domain (residues 135–138) adopted an
extended ‘‘b strand-like’’ conformation—supported by unam-
biguous electron density (Figure 2B; Figure S1 available
online)—in contrast to the turn-like FG loop conformation found
in the classical IgV domain structures. As a result, the IgV domain
of dimeric mB7H3 consists of a b sandwich composed of a
‘‘back sheet’’ (BED) and a ‘‘front sheet’’ (C00C0CFG*), the latter
of which includes the G* strand contributed by the second
protomer.
The C-terminal IgC domain (residues 140–239) consists of a
typical b sandwich composed of sheets ABED and CFG (Sun
and Boyington, 2001). Topologically, this places both IgC
domains on the opposite ends of the elongated mB7H3 dimer,
with the C termini separated by 155 A˚.
The mB7H3 sequence contains four potential glycosylation
sites: N91, N104, N189, and N215. Electron density that could
be interpreted as a single N-acetyl glucosamine (NAG) moiety
was present near N91. In the case of N104, three well-orderedStructure 21sugar residues were observed, corresponding to two NAG and
two mannose units. Notably, the location of the glycans on the
mB7H3 IgV domain corresponds to the domain’s back sheet,
consistent with the hypothesis that the front sheet engages
the receptor, as shown for other B7 family members.
Although the dimer assembly observed in the crystals is stable
in solution (see below), mB7H3 was initially purified as a mono-
mer (Figure 1C), which is likely the dominant form present on
the cell surface. To generate a model of the monomeric form of
mB7H3, we built a ‘‘hybrid’’ model consisting of residues
35–125 from one protomer and residues 130–238 from its
2-fold symmetry-related mate (Figure 2C); predicted FG loop
residues (126–129) were modeled as a b turn using the
ArchPRED software (Fernandez-Fuentes et al., 2006). The result-
ing monomeric mB7H3 model aligns well with a representative
B7 family member structure—i.e., human PD-L1 (Protein Data
Bank [PDB] 3BIK, chain A; overall Ca rmsd 2.7 A˚, IgV Ca
rmsd1.1 A˚; Figure 2D)—indicating that the overall organization
of the proposed mB7H3 monomer is consistent with those of
other B7 family members.
The FG Loop Is Important for mB7H3-Mediated
Inhibition of T Cell Proliferation
Guided by the receptor-binding properties of other Ig super-
family members and the model of monomeric mB7H3, we
generated a panel of mutants targeting the surface residues
of the front sheet of the N-terminal IgV domain, including the
FG loop (Figure 3B). This surface has been shown to play
a critical role in receptor recognition for a number of B7 family
members, including B7-1 (Stamper et al., 2001), B7-2 (Schwartz
et al., 2001), PD-L1 (Lin et al., 2008), and PD-L2 (La´za´r-Molna´r
et al., 2008).
B7-H3 function has been previously evaluated in T cell prolif-
eration assays (Chapoval et al., 2001; Suh et al., 2003; Prasad
et al., 2004). In our assay, purified proteins were immobilized
on plastic tissue culture plates in the presence of monoclonal
anti-murine-CD3 antibody (which was used to engage the
TCR-mediated ‘‘signal 1’’). To ensure a homogeneous T cell acti-
vation state, TCR-transgenic OT-II cells were used in these ex-
periments. CD4+ T cells, freshly isolated from OT-II mice, were
incubated in these plates to compare cell proliferation in the
presence of wild-type (WT) or mutant mB7H3 proteins (the
optimal mB7H3 concentration was determined, as shown in Fig-
ure 3A). To eliminate possible complications associated with
mB7H3 dimers, freshly purified protein stocks were kept at con-
centrations below 2 mg/ml (details of mB7H3 dimerization are
described below).
The presence of WT mB7H3 consistently resulted in an
50% decrease in T cell proliferation compared to control con-
ditions (PBS or rat IgG), indicating that mB7H3 delivered a
signal that was inhibitory to T cells (Figure 3C). In this assay,
the greatest effect was associated with the exchange of the
B7-H3 FG loop sequence with the corresponding sequence
from human PD-L1. This chimeric FG loop mutant (I126Y/
Q127G/D128G/F129A) showed a consistent and significant
(p < 0.05) difference with respect to the WT mB7H3, resulting
in a nearly complete loss of inhibitory activity (Figure 3C). In
contrast, FG loop point mutants I126T and F129A were not
significantly different from WT mB7H3. Surprisingly, none of, 707–717, May 7, 2013 ª2013 Elsevier Ltd All rights reserved 709
Figure 2. Structure of mB7H3
(A) Crystals of mB7H3 contain the dimeric form of
the protein. Ribbon representation of the crystal-
lographic dimer of mB7H3 with each protomer
drawn in different colors (gray and cyan) with N
and C termini labeled for one of the protomers.
Unmodeled residues 152–156 of the IgC domain
of each protomer are shown with dots of corre-
sponding color. The glycans (two on each proto-
mer) are drawn in stick representation. Strands
making up the Ig fold in each domain are labeled in
yellow, whereas the strand exchanged between
the two protomers (G*) is labeled in pink.
(B) Electron density of the extended FG loop-
bridging sequence. FoFc electron density map,
calculated with the FG loop sequence omitted,
contoured at +3s is shown in green near the
location of the strand exchange highlighted by a
box in (A). Ribbon diagrams representing the
structure for each mB7H3 protomer are shown.
The side chains of the FG loop residues are shown
in gray stick-figure representation.
(C) Structure-based model of monomeric mB7H3.
Model of the mB7H3 monomer was constructed
by combining residues 35–125 from one protomer
and residues 130–238 from its 2-fold-related
symmetry mate.
(D) Monomeric model of mB7H3 corresponds well
to the PD-L1 structure. Structural alignment
(overall Ca rmsd2.7 A˚) of the monomeric mB7H3
model (gray) and the structure of human PD-L1
(purple).
See also Figure S1.
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B7-H3 Structure and T Cell Inhibitor Functionthe point mutants that targeted the front sheet of the mB7H3
IgV domain resulted in a statistically significant change in OT-
II T cell inhibition. Similar data were obtained using CD4+
T cells isolated from C57BL/6 mice (which express a normal
T cell repertoire, in contrast to OT-II mice), with the exception
of the T121A mutant, which was significantly impaired in its
inhibitory function compared to WT mB7H3 (Figure S2). Taken
together, these data show that receptor recognition by B7-H3
involves the residues of the FG loop but that mutation of individ-
ual front sheet residues to alanine is insufficient to disrupt its
T cell inhibitory function.
B7-H3 Does Not Bind TLT-2
The identity of the receptor(s) responsible for the T cell coinhibi-
tory and costimulatory effects of B7-H3 has not been conclu-
sively established. Although expression of the triggering recep-
tor expressed on myeloid cell (TREM)-like transcript-2 (TLT-2)
has been reported to specifically bind B7-H3 and result in B7-710 Structure 21, 707–717, May 7, 2013 ª2013 Elsevier Ltd All rights reservedH3-dependent T cell stimulation (Hashi-
guchi et al., 2008), these findings could
not be reproduced in similar experi-
mental systems using murine or human
cells (Leitner et al., 2009). To address
these discrepancies, we expressed the
ectodomain of murine TLT-2 as a
secreted His6-tagged protein (mTLT2)using S2 cells and found that mTLT2 and mB7H3 did not bind
to each other in SEC or surface plasmon resonance experi-
ments (data not shown). Furthermore, murine B7-H3 Ig fusion
could not bind TLT-2-expressing cells in flow cytometry exper-
iments (data not shown). These observations suggest that TLT-
2 is not a binding partner for B7-H3.
mB7H3 Forms a Stable Dimer upon Extended Incubation
at High Protein Concentration
Stock solutions of purified mB7H3 used in crystallization exper-
iments were routinely concentrated to >10 mg/ml and stored at
4C. Following extended storage (>3 weeks), we observed a
time- and concentration-dependent accumulation of a high
molecular weight protein species by SEC (Figures 4A and 4B).
This SEC peak eluted at a volume corresponding to a protein
of 80 kDa—double that of monomeric mB7H3—and did not
revert to the original SEC elution profile (corresponding
to 40 kDa) following purification and dilution (data not shown).
Figure 3. Functional Characterization of mB7H3 Wild-Type and Mutants
(A) CD4+ T cell proliferation is inhibited by mB7H3 in a dose-dependent manner. CD4+ OT-II cells were cultured in plasticware pretreated with the proteins
indicated below the x axis. T cell proliferation was assayed by pulsing with [3H]thymidine during the last 18 hr of a 3 day incubation. Average values obtained from
four replicates are shown with error bars representing the SEM.
(B) Mapping of front sheet and FG loop mutations on the structure of mB7H3. The N-terminal IgV domain of mB7H3 monomer is shown in ribbon diagram (gray).
Residues of the FG loop (red) and mutated front sheet positions (blue) are labeled and shown with side chains represented as stick figure.
(C) T cell proliferation is inhibited by WT, but not the FG loop chimera of mB7H3. CD4+ OT-II T cells were cultured in 96-well plates precoated with 0.5 mg/ml
anti-CD3 and 5 mg/ml proteins indicated along the x axis. T cell proliferation was assayed by pulsing with [3H]thymidine during the last 18 hr of a 3 day incubation.
Data were normalized to the mean value obtained for anti-CD3 alone (PBS). Average values obtained from two experiments (four replicates per sample per
experiment) are shownwith error bars representing the SEM. Statistically significant differences (p < 0.05, ANOVA) with respect to theWTmB7H3 sample (double
dagger) are labeled with asterisks.
See also Figure S2.
Structure
B7-H3 Structure and T Cell Inhibitor FunctionSDS-PAGE analysis indicated that this protein species was
indistinguishable from the original mB7H3 sample, when dena-
tured (Figure 1B). Furthermore, the complex was found to
contain no interchain disulfide bonds when separated under
nonreducing conditions (Figure 1B).
To identify the physicochemical properties responsible for
mB7H3 dimer formation, we subjected monomeric mB7H3 to a
range of ionic strengths, redox conditions, pHs, and tempera-
tures. None of the conditions tested promoted dimer formation
(data not shown).
Dimerization of mB7H3 Is Perturbed by Mutations in the
FG Loop
The four-residue sequence I(Q/R)DF (126–129) of the FG loop in
B7-H3 is conserved among the mammalian B7-H3 sequences
(Figure 5A). It is also strikingly different from the cor-
responding YGGA sequence, conserved in the homologous
murine PD-L1 (Figure 5B), structure of which has been previ-
ously reported (PDB 3BIK, 3BIS, 3SBW, and 3FN3). Based on
the fact that in our structure, the FG loop sequence adopts a
strand-like conformation, we hypothesized that it may play a
role in mB7H3 dimerization. To assess this possibility, we moni-
tored the dimerization of mutants I126T, F129A, and the FG
loop chimera (I126Y/Q127G/D128G/F129A) (Figure 6A).
Each mutant was expressed and purified using the S2
Drosophila system described above, and dimer formation was
evaluated by SEC, as described for the WT mB7H3. Compared
to that of WT mB7H3, dimer formation was significantly slower
for mutants I126T and the FG loop chimera, whereas mutant
F129A exhibited behavior similar to the WT mB7H3 (Figure 6B;
Table 2).Structure 21Both Monomeric and Dimeric mB7H3 Inhibit the
Proliferation of CD4+ T Cells
In order to determine whether dimerization plays a role inmB7H3
function, we compared monomeric mB7H3 to predimerized
samples in the T cell proliferation assay described above.
Freshly purified protein stocks were kept at concentrations
below 2 mg/ml to prevent mB7H3 dimerization, and the dimeric
samples were verified to be stably dimeric over the course of the
experiments (data not shown).
As described above,WTmonomeric mB7H3 caused a consis-
tent 50% decrease in T cell proliferation compared to control
conditions (PBS or rat IgG), indicating that mB7H3 delivered an
inhibitory signal to the T cells (Figure 6C, ‘‘WT monomer’’),
whereas the replacement of the FG loop caused near loss of
the inhibition (Figure 6C, ‘‘FG chimera’’). In order to test the
dimeric form of mB7H3, a sample undergoing dimerization and
containing 40% mB7H3 dimer was separated by SEC, and
the resulting monomer and dimer fractions were tested (Fig-
ure 6C, samples ‘‘WT monomer*’’ and ‘‘WT dimer*’’). We found
that dimeric mB7H3 did not significantly differ from the mono-
meric form in its ability to inhibit T cell proliferation. This indicates
that dimerization of mB7H3 alone does not alter the inhibitory
property on the molecule.
DISCUSSION
B7-H3 Structure
Here, we present the structure of the murine B7-H3 ectodomain,
which reveals a noncanonical quaternary structure previously
described for other members of the Ig superfamily. We observed
mB7H3 dimers formed by an unusual strand/domain swap, 707–717, May 7, 2013 ª2013 Elsevier Ltd All rights reserved 711
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Figure 4. mB7H3 Forms Stable Dimers in Solution
(A) Purified mB7H3 dimerizes during incubation. Protein samples were
concentrated to 1.6 mM (60 mg/ml) and incubated at 4C. SEC traces
represent experiments carried out at the time points indicated. Monomer (M)
and dimer (D) peaks are labeled.
(B) WT mB7H3 dimerizes over time in a concentration-dependent manner.
SEC time course data similar to those shown in (A) were obtained for the
indicated concentrations of WT mB7H3. Each data point represents the pro-
portion of dimer observed (as measured by dimer peak height) compared to
the total (monomer peak height plus dimer peak height).
A
B
Figure 5. Sequence Conservation of the FG Loop
(A) Sequence of the B7-H3 FG loop is conserved. Clustal W (Larkin et al., 2007;
Goujon et al., 2010) was used to align the mB7H3 sequences from eight
mammalian species, and the resulting alignment is presented using ESPript
(Gouet et al., 1999). Secondary structural elements of the mB7H3 structure are
labeled (top line). Sequence differences are shown as red lettering on black
background. The four FG loop residues are highlighted with yellow back-
ground.
(B) Sequence of the FG loop is divergent between B7 family members. Clustal
W (Larkin et al., 2007; Goujon et al., 2010) sequence alignment of murine and
human sequences of B7-H3 and PD-L1 is shown. Positions identical in all
sequences are shown in green lettering with gray background. The four FG
loop residues are highlighted with yellow background.
Structure
B7-H3 Structure and T Cell Inhibitor Functionbetween partner molecules (Figure 2A), resulting in an elongated
assembly with the C termini separated by155 A˚. Notably, crys-
tals formed only from protein stocks that had been stored for
several weeks following purification, while freshly purified sam-
ples failed to yield crystals. Furthermore, we did not identify
any crystallization conditions for the FG loop chimera, which
was severely impaired in its capacity to dimerize (Figure 6B).
The dimeric arrangement is stabilized by the exchange of the F
strands in the partner molecules within the IgV fold of the N-ter-
minal domain. The sequence connecting the F and G strands,
which normally forms the FG loop, is fully extended in the dimer
and forms a short two-stranded bridge between the two proto-
mers. This organization is distinct from the typical mode of
dimerization in the Ig superfamily, which involves contacts
between the two front sheets of the IgV domains from interacting
partner molecules (reviewed in Chattopadhyay et al., 2009).
Nevertheless, similar dimers have been described for at least
three other members of the Ig superfamily: the llama antibody
VHH-R9 domain (Spinelli et al., 2004); the human CD47 IgV
domain (Hatherley et al., 2008); and the CTLA-4 IgV domain
(Sonnen et al., 2010) (Figure 7). According to these reports, dimer
formation was not detected in solution, although all of thesemol-
ecules crystallized as dimers linked by the swap of the G strand712 Structure 21, 707–717, May 7, 2013 ª2013 Elsevier Ltd All rights(similar to the mB7H3 structure reported here). In addition,
CTLA-4 IgV domain spontaneously forms amyloid aggregates.
In addition to yielding the structure of the dimeric form of
mB7H3, our data provided us with a plausible model of its
monomeric precursor (Figure 2C). In particular, the overall super-
position of the mB7H3 monomeric model and the human PD-L1
structure (3BIK) demonstrates that the individual IgV and IgC
domain folds, as well as their positions with respect to one
another, align well (Figure 2D). This observation suggests that
the invading G strand from each of the protomers occupies a po-
sition in the accepting IgV domain of its partner molecule that is
equivalent to its position in the monomeric precursor.
B7-H3 Function
The precise function of B7-H3 remains unclear because it has
been reported to stimulate (Chapoval et al., 2001; Hashiguchi
et al., 2008; Kobori et al., 2010), inhibit (Suh et al., 2003; Prasad
et al., 2004; Xu et al., 2006; Leitner et al., 2009; Chen et al.,
2011), and have no effect (Steinberger et al., 2004) on T cell pro-
liferation in various experimental systems. Understanding the
role that B7-H3 plays in immunity is further confounded by
the fact that B7-H3-deficient mice are generally healthy and
have normal cellular compositions of their immune compart-
ments (Suh et al., 2003), suggesting that the loss of B7-H3
function in these animals can be compensated for by other
mechanisms. Nevertheless, most reports to date suggest that
T cells express an unidentified receptor(s) that binds to
B7-H3, resulting in a modulation of the T cell response to
antigen-dependent signals.reserved
Figure 6. Functional Characterization of mB7H3 Monomer and Dimer
(A) Mapping FG loopmutations on the structure of mB7H3. The N-terminal IgV domain of mB7H3monomer is shown in ribbon diagram (gray). Residues of the FG
loop (black) are labeled and shown with side chains represented as stick figures.
(B) Mutations at the FG loop disrupt dimerization of mB7H3. Dimer formation was measured for mB7H3 FG loop mutants using experiments similar to those
shown in Figure 4A.
(C) T cell proliferation is inhibited by monomeric and dimeric WT, but not the FG loop chimera of mB7H3. CD4+ OT-II cells were cultured in 96-well plates
precoated with 0.5 mg/ml anti-CD3 and 5 mg/ml of the proteins indicated along the x axis. T cell proliferation was assayed by pulsing with [3H]thymidine during the
last 18 hr of a 3 day incubation. Data were normalized to the mean value obtained for the treatment with anti-CD3 alone (PBS). Average values obtained from two
experiments (four replicates per sample per experiment) are shown with error bars representing the SEM. Statistically significant differences (p < 0.05, ANOVA)
with respect to the WT mB7H3 sample (double dagger) are labeled with asterisks.
Structure
B7-H3 Structure and T Cell Inhibitor FunctionIn order to study the biological activity of mB7H3, we tested
purified protein samples in an in vitro system similar to those
described earlier by Prasad et al. (2004), Hashiguchi et al.
(2008), and Suh et al. (2003). Although we initially used C57BL/
6-derived T cells, we found that the experimental variation was
significantly lower with the cells isolated fromOT-II mice. Despite
the differences, the data from these two mouse strains were,
generally, in agreement. CD4+ T cells isolated from either
C57BL/6 or OT-II mice showed a reproducible 50% inhibition
of proliferation when cultured in tissue culture plates pretreated
with a combination of anti-CD3 and WT mB7H3, compared to
control conditions (anti-CD3 alone or in combination with an
irrelevant protein) (Figures 3C and S2). Thus, in our system, we
observed that B7-H3 plays an inhibitory role in T cell activation.
Based on the similar modes of receptor recognition among the
B7 family members (La´za´r-Molna´r et al., 2008; Lin et al., 2008;
Stamper et al., 2001; Schwartz et al., 2001), we hypothesized
that the residues located on the surface of the front sheet of
the IgV domain are involved in recognition of the B7-H3 receptor.
A number of mutants on the front sheet surface (I126T, F129A,
F123A, I66A, L75A, T121A, Q68A, S78A) had inhibitory activities
that could not be distinguished from that of WTmB7H3 using the
OT-II cells (Figure 3C) or the C57BL/6-derived cells (with the
exception of the T121A mutant, which showed a significant
impairment) (Figure S2). Taken together, our data suggest that
either the individual contributions of these residues are insuffi-
ciently strong to be detected in our assay or that this molecular
surface does not make major contributions to recognition by
the receptor.
In contrast, simultaneousmultiple mutations resulting from the
replacement of the FG loop with the corresponding sequence
from murine PD-L1 (FG chimera) resulted in a nearly complete
loss of inhibition of OT-II cells (Figure 3C) and a significantStructure 21impairment of inhibition of C57BL/6-derived cells (Figure S2).
These data indicate that the FG loop residues are involved in
B7-H3 interaction with the receptor expressed on T cells.
Recombinant B7-H3 Dimerization
We demonstrated that mB7H3 spontaneously dimerizes under
physiologic pH and ionic strength. This behavior raises ques-
tions as to whether the mB7H3 dimer represents a physiologi-
cally significant species. In particular, how can the slow kinetics
support significant dimer formation in vivo? At least three
hypotheses emerge: (1) topological restrictions imposed by the
association with the plasma membrane of interacting cells
may provide a stabilizing environment during monomer/dimer
transition under physiologic conditions; (2) additional mem-
brane-associated molecules facilitate the process of mB7H3
dimer formation on the cell surface or in an intracellular compart-
ment; or (3) the crystallographically observed mB7H3 dimer may
be an in vitro artifact with no in vivo correlate.
Based on the comparison between the model of the mB7H3
monomer and the observed dimer structure, we hypothesized
that the sequence connecting the strands F and G of the IgV
domain can adopt at least two conformations (extended and b
turn-like) and thus plays a role in the ability of B7-H3 to dimerize.
To address this hypothesis, we generated a series of mutants
targeting the loop connecting the F and G strands. Introduction
of the FG loop sequence (YGGA) from PD-L1, containing the
highly flexible Gly-Gly pair of residues, severely impaired dimer
formation with an 18-fold reduction in the rate of dimerization.
Additionally, when modeled in the b turn conformation (i.e., in
the monomeric form), the predicted geometry of the mB7H3 FG
loop would cause the hydrophobic residue Ile-126 to be more
solvent exposed, than in the extended conformation observed
in dimeric mB7H3. In the latter case, the Ile-126 side chain, 707–717, May 7, 2013 ª2013 Elsevier Ltd All rights reserved 713
Figure 7. Strand-Swapped Dimer Formation among the Members of
the Ig Superfamily
Structures of strand-swapped dimers of IgV domains. N-terminal IgV domain
dimer of mB7H3 (A), CD47 (B), CTLA-4 (C), and llama VHH-R9 Ig (D). Each
protomer is labeled in different colors (green and red), with N termini labeled.
Strands making up the two b sheets of the Ig fold are labeled (yellow), and the
swapped strand (G*) is labeled in black.
Table 2. Dimerization Kinetics of mB7H3 and Mutants
Mutation FG Loop Sequence
Association Rate Constant
3 105 (l/mol/s)
WT IQDF 16.1 ± 0.6
I126T TQDF 4.1 ± 0.1
F129A IQDA 16.4 ± 0.3
FG chimera YGGA 0.83 ± 0.08
Values were determined using the fitting analysis shown in Figure S3.
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and Phe-58, stabilizing the extended conformation of themB7H3
protomer and the dimer itself. Introduction of the I126T muta-
tion in mB7H3 resulted in an 3-fold reduction in the dimeriza-
tion rate, supporting the hypothesis that hydrophobicity of
Ile-126 contributes to dimer formation. Taken together, our
analysis of the FG loop in mB7H3 suggests that the WT
sequence may play a destabilizing role for the monomeric form
of mB7H3.
Implications of B7-H3 Dimerization for Biological
Function
The functional relevance of strand-swapped dimer formation
among the Ig superfamily members is not clear. Of the known
examples, strand exchange of the llama antibody VHH domain
would render it incapable of engaging antigen due to the re-
modeling at the antigen-binding site. In CD47, the N-terminal
IgV domain is topologically constrained with respect to the
C-terminal portions of the molecule, making it unlikely to partic-
ipate in the strand-swap dimerization while expressed on the
cell surface. On the other hand, amyloid fiber formation by
CTLA-4 suggests a potential mechanism by which strand
swapping may lead to a variety of diseases associated with
Ig deposition (Bennett et al., 2006). Although B7-H3 has not
been implicated in amyloid-caused disease, our data lend
credence to the notion that IgV domains may exhibit unantici-
pated plasticity.
The B7-H3 dimer structure reported here positions the trans-
membrane regions of the molecule at an 155 A˚ distance. This
arrangement is suggestive of a mechanism by which homo-
philic B7-H3 interactions may bridge two interacting cells and
may possibly represent a ligand:ligand or a ligand:receptor
complex (in which case, one or both of the B7-H3 molecules
would facilitate signaling to its parent cell). Interestingly, our
structure predicts that if the front sheet of the B7-H3 IgV
domain is involved in receptor recognition, the binding surface
would be accessible in the dimeric form of B7-H3. Furthermore,
in our experiments, the mB7H3 dimer had the same inhibitory
activity as the monomer in the T cell proliferation assay (Fig-
ure 6C), which is consistent with this notion. However, due to
the slow rate of mB7H3 dimer formation measured in solution
(Table 2), it is likely that additional mechanisms are involved
in facilitating B7-H3 dimerization, if it plays a role in B7-H3
function.
Finally, we have shown that the inhibitory activity ofmB7H3 FG
chimera is severely impaired and that this mutant is also
impaired in its ability to dimerize in solution. Although these ob-
servations are intriguing, we believe that they are unlikely to be714 Structure 21, 707–717, May 7, 2013 ª2013 Elsevier Ltd All rightsrelated for the following reasons: (1) the monomeric and dimeric
forms of mB7H3 are functionally equivalent in our T cell prolifer-
ation assays (Figure 6C), and (2) the I126T mutant is functional in
the T cell proliferation assays (Figures 6C and S2) but is signifi-
cantly impaired in its dimerization properties (Figure 6B). Thus,
our data lead us to conclude that whereas both conformations
of the FG loop are equally functional, the identities of the resi-
dues of the FG loop are critical for receptor recognition.
In summary, we determined the structure of murine B7-H3 and
used it to characterize the molecular determinants responsible
for receptor recognition. A growing body of literature suggests
that B7-H3 is a key factor in the progression of many cancers
and highlights the importance of studies of the biology of this
molecule as well as its binding partners, which control the im-
mune response at tumor sites. Although the precise role that
B7-H3 plays in in vivo T cell regulation remains to be defined,
we demonstrated that it has a clear inhibitory function in our
assay system and identified the FG loop sequence in its IgV
domain as important for this function. The development of
therapeutics specifically targeting this sequence may prove use-
ful as an anticancer drug strategy.reserved
Structure
B7-H3 Structure and T Cell Inhibitor FunctionEXPERIMENTAL PROCEDURES
DNA Cloning
DNA encoding the predicted extracellular fragment of murine B7-H3 (amino
acids 34–247) was amplified by PCR using primers containing BglII and AgeI
restriction sites and cloned into the pMT/BiP/V5-His A (Invitrogen) or the
pCGMbX vectors, which includes a constitutively expressed egfp gene. Con-
structs containing mutations of single residues and contiguous spans were
generated using QuikChange Site-Directed Mutagenesis Kit (Stratagene).
Cell Lines
Express Five SFM (Invitrogen) was used for routine culture and recombinant
protein expression using Drosophila S2 cells. Schneider’s Drosophila
Medium (Invitrogen), supplemented with 10% fetal bovine serum, was
used when transfecting the cells using the calcium phosphate method (Invi-
trogen). Alternatively, transfection was performed using the dimethyl diocta-
decyl ammonium bromide (DDAB) method (Han, 1996) in Express Five SFM.
Following cotransfection of the target-containing vector and the selection
vector (pCoBlast or pCoPuro; mixed at a ratio of 1:20 with the target-contain-
ing vector), the cells were allowed to recover for 48 hr before being
selected with either 25 mg/ml Blasticidin S (Invitrogen) or 10 mg/ml puromycin
(Fisher). To improve protein expression, drug-resistant cell populations were
subcloned using a modified version of the limited dilution method by Yang
et al. (2004). Briefly, parental S2 feeder cells were irradiated (20,000 rads)
and coplated with target stable cell populations at a ratio of 250,000:3
(feeder:target) per well of a 96-well plate. The target cells were allowed to
form colonies over the course of 2–3 weeks while being supplemented
with fresh medium every 4–6 days. The colonies were then resuspended
and replica plated into an induction plate containing fresh medium supple-
mented with 1 mM copper sulfate. Following a 7 day incubation, the super-
natants from the induction plate were screened by dot blot using Penta-His
antibody (QIAGEN) to identify the high expressors among the stable cell line
populations.
Animals
C57BL/6 and OT-II mice were purchased from The Jackson Laboratory
(Bar Harbor, ME, USA) and maintained under pathogen-free conditions
at the Albert Einstein College of Medicine. OT-II mice carry an MHC class
II-restricted chicken ovalbumin-specific TCR transgene, thus narrowing the
specificity of their entire T cell repertoire to just this antigen. Mice were
used in the experiments at 6–12 weeks of age. All animal work was per-
formed according to the guidelines set by the Institutional Animal Care and
Use Committee.
Protein Expression and Purification
Cell lines were expanded in shaker-flask suspension cultures and inducedwith
1 mM copper sulfate. Cultures were harvested 7 days postinduction, centri-
fuged to remove cells and debris, supplemented with 150 mM NaCl and
0.02% sodium azide, and filtered using 0.22 mm membrane. The resulting
clarified supernatants were flowed over a column containing Ni-NTA agarose
(QIAGEN), washed with TBS (20 mM Tris-HCl [pH 8], 300 mM NaCl, 0.02%
sodium azide), TBS plus 20 mM imidazole, and eluted using TBS plus
200 mM imidazole. Eluted protein was concentrated and further purified using
gel filtration on Superdex 200 resin in HBS-E buffer (20 mM HEPES [pH 7],
150 mM NaCl, 1 mM EDTA).
Crystallization, Data Collection, and Modeling
Diffraction-quality crystals were grown in sitting-drop crystallization reactions
containing 1 ml of protein solution (10 mg/ml in HBS-E) and 1 ml reservoir
solution (0.1 M HEPES [pH 7.5] and 20% polyethylene glycol 10,000 [w/v]).
Crystals were cryoprotected in reservoir solution supplemented with 20%
ethylene glycol (v/v) prior to flash cooling in liquid nitrogen. X-ray diffrac-
tion data were collected at beamlines 24-ID-E (Advanced Photon Source,
Argonne, IL, USA) and X29 (National Synchrotron Light Source, Upton,
NY, USA).
Data were integrated using the iMOSFLM (Battye et al., 2011) software with
subsequent processing using the programs within the CCP4 software
package (Winn et al., 2011). An initial structure, based on the structure ofStructure 21human PD-L1 (PDB 3BIK), was determined using the BALBES software
package (Long et al., 2008). The model was further built using Coot (Emsley
et al., 2010) and refined using REFMAC5 (Murshudov et al., 1997).
Dimerization Kinetics Measurements
Concentrated WT and mutant mB7H3 protein stocks were serially diluted in
HBS-E buffer and incubated at 4C. Aliquots containing 50 mg of protein
were separated on a standardized analytical Superdex 200 sizing column,
and the peak heights (absorbance at 280 nm) corresponding to monomer
and dimer protein species were recorded for the duration of each time
course. Concentrations of monomer and dimer species were estimated
based on the fraction of peak heights of each component with respect to
total protein amount. These data were used to generate a global fit (using
data from multiple concentrations of each protein) against a model for
a second-order reaction rate law (as shown in Figure S3) using GraphPad
Prism (v.5) software to obtain the apparent association rate constants shown
in Table 2.
T Cell Proliferation Assays
CD4+ T cells were isolated from the spleens and superficial lymph nodes of 6-
to 8-week-old OT-II or C57BL/6 mice using mouse CD4 Dynabeads and
DETACHaBEADs (Invitrogen). A total of 2 3 105 purified CD4+ T cells were
plated into each well of a 96-well cell culture plate precoated (for 16 hr at
4C) with 0.5 mg/ml solution of CD3ε antibody (BD Biosciences), also contain-
ing the indicated amounts of WT mB7H3 monomer, mB7H3 dimer, mB7H3
mutants, rat IgG2b (BioExpress), as a protein control, or a PBS control. [3H]
thymidine (PerkinElmer) was added for the last 18 hr of the 72 hr cultures,
and T cell proliferation was measured by detecting 3H incorporation using a
Wallac MicroBeta 1450 TriLux Liquid Scintillation Counter. Where indicated,
data were normalized with respect to the average signal obtained with
anti-CD3/PBS control. Replicates of at least four wells were used for each
condition, and the experiments were repeated two to five times. Optimal
concentrations of anti-CD3 and monomeric mB7H3—specific to our assay
system—were determined by dose-response titration experiments such as
the one shown in Figure 3A. The data were analyzed using one-way ANOVA
followed by Dunnett’s multiple comparison test (GraphPad Prism, v.5);
p values < 0.05 were considered significant. For more details, please see
Supplemental Experimental Procedures.
ACCESSION NUMBERS
The structure factors and the final model coordinates have been deposited into
the Protein Data Bank and have been assigned the accession number 4I0K.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.str.2013.03.003.
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